{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T11:06:19Z","timestamp":1768647979838,"version":"3.49.0"},"reference-count":52,"publisher":"Ubiquity Press, Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,31]]},"DOI":"10.5334\/tohm.672","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T11:43:51Z","timestamp":1640951031000},"source":"Crossref","is-referenced-by-count":14,"title":["Primidone Intolerance in Essential tremor: Is it More than Just Age?"],"prefix":"10.5334","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-636X","authenticated-orcid":false,"given":"Abhishek","family":"Lenka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2062-362X","authenticated-orcid":false,"given":"Elan D.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3285","reference":[{"key":"key20211231064346_B1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5334\/tohm.198","article-title":"How Many People in the USA Have Essential Tremor? Deriving a Population Estimate Based on Epidemiological Data","volume":"4","year":"2014","journal-title":"Tremor and Other Hyperkinetic Movements"},{"key":"key20211231064346_B2","article-title":"How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor","volume":"11","journal-title":"Tremor and Other Hyperkinetic Movements"},{"key":"key20211231064346_B3","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/mds.27700","article-title":"MDS evidence-based review of treatments for essential tremor","volume":"34","year":"2019","journal-title":"Movement Disorders"},{"key":"key20211231064346_B4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1468-1331.2009.02926.x","article-title":"How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ETon medication: Data from 528 patients in three settings","volume":"17","year":"2010","journal-title":"Eur J Neurol"},{"key":"key20211231064346_B5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/bmj.282.6259.178","article-title":"Benign familial tremor treated with primidone","volume":"282","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"key20211231064346_B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.44.7.650","article-title":"Essential tremor: Response to primidone","volume":"44","year":"1981","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"key20211231064346_B7","first-page":"117","article-title":"Primidone therapy for essential vocal tremor","year":"2016","journal-title":"JAMA Otolaryngology \u2013 Head and Neck Surgery"},{"key":"key20211231064346_B8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/jnnp.44.10.932","article-title":"Phenylethylmalonamide in essential tremor. A double-blind controlled study","volume":"44","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20211231064346_B9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/bmj.285.6342.608","article-title":"Double-blind controlled study of primidone in essential tremor: Preliminary results","volume":"285","year":"1982","journal-title":"Br Med J"},{"key":"key20211231064346_B10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jnnp.48.9.911","article-title":"Primidone in essential tremor of the hands and head: A double blind controlled clinical study","volume":"48","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20211231064346_B11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.36.1.121","article-title":"Efficacy of primidone in essential tremor","volume":"36","year":"1986","journal-title":"Neurology"},{"key":"key20211231064346_B12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-0404.1987.tb05455.x","article-title":"Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels","volume":"75","year":"1987","journal-title":"Acta Neurol Scand"},{"key":"key20211231064346_B13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF00314310","article-title":"Primidone and essential tremor","volume":"235","year":"1988","journal-title":"J Neurol"},{"key":"key20211231064346_B14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.38.5.808","article-title":"Double-blind comparison of primidone and phenobarbital in essential tremor","volume":"38","year":"1988","journal-title":"Neurology"},{"key":"key20211231064346_B15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002826-199002000-00007","article-title":"Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis","volume":"13","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"key20211231064346_B16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000492831","article-title":"The roles of age and aging in essential tremor: An epidemiological perspective","volume":"52","year":"2019","journal-title":"Neuroepidemiology"},{"key":"key20211231064346_B17","first-page":"1066","volume-title":"Encyclopedia of Toxicology","year":"2014"},{"key":"key20211231064346_B18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/FTD.0b013e3182843206","article-title":"A Child Exposed to Primidone Not Prescribed for Her","volume":"35","year":"2013","journal-title":"Ther Drug Monit"},{"key":"key20211231064346_B19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/jnnp.49.1.64","article-title":"A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis","volume":"49","year":"1986","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20211231064346_B20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1353-8020(03)00070-1","article-title":"Use of primidone in low doses (250 mg\/day) versus high doses (750 mg\/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up","volume":"10","year":"2003","journal-title":"Park Relat Disord"},{"key":"key20211231064346_B21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ncl.2020.01.002","article-title":"Current and Emerging Treatments of Essential Tremor","volume":"38","year":"2020","journal-title":"Neurologic Clinics"},{"key":"key20211231064346_B22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cpt1974161part2243","article-title":"Pharmacodynamic and pharmacokinetic measurements of antiepileptic drugs","volume":"16","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"key20211231064346_B23","first-page":"1743","article-title":"Duration of effectiveness of primidone in essential tremor","volume":"36","year":"1986","journal-title":"Neurology"},{"key":"key20211231064346_B24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.1966.03110190151046","article-title":"Drug-Induced Systemic Lupus Erythematosus: Primidone as a Possible Cause","volume":"198","year":"1966","journal-title":"JAMA J Am Med Assoc"},{"key":"key20211231064346_B25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/NRL.0000000000000240","article-title":"Dupuytren, Ledderhose, and Peyronie Diseases after Primidone Use for Essential Tremor","volume":"24","year":"2019","journal-title":"Neurologist"},{"key":"key20211231064346_B26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM195502242520803","article-title":"Mysoline; an effective anticonvulsant with initial problems of adjustment","volume":"252","year":"1955","journal-title":"N Engl J Med"},{"key":"key20211231064346_B27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/mds.10083","article-title":"Randomized trial comparing primidone initiation schedules for treating essential tremor","volume":"17","year":"2002","journal-title":"Mov Disord"},{"key":"key20211231064346_B28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00007691-198406000-00010","article-title":"Development of tolerance to the side effects of primidone","volume":"6","year":"1984","journal-title":"Ther Drug Monit"},{"key":"key20211231064346_B29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical Side Effects of Phenobarbital, Primidone, Phenytoin, Carbamazepine, and Valproate During Monotherapy in Children","volume":"29","year":"1988","journal-title":"Epilepsia"},{"key":"key20211231064346_B30","first-page":"570","article-title":"Mysoline in treatment of epileptic and non-epileptic psychiatric patients","volume":"68","year":"1953","journal-title":"Can Med Assoc J"},{"key":"key20211231064346_B31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(54)90760-6","article-title":"Primidone in the treatment of Non-idiopathic epilepsy","volume":"263","year":"1954","journal-title":"Lancet"},{"key":"key20211231064346_B32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/adc.29.146.323","article-title":"Mysoline\u2019 in the treatment of recalcitrant idiopathic major epilepsy in mentally defective children","volume":"29","year":"1954","journal-title":"Arch Dis Child"},{"key":"key20211231064346_B33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.2.4888.627","article-title":"Primidone in Mental Deficiency Practice","volume":"2","year":"1954","journal-title":"Br Med J"},{"key":"key20211231064346_B34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM195602162540706","article-title":"Primidone (Mysoline) in the Treatment of Epilepsy","volume":"254","year":"1956","journal-title":"N Engl J Med"},{"key":"key20211231064346_B35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00005053-195612000-00008","article-title":"Chlorpromazine and mysoline in the control of convulsive epilepsy in mentally deficient patients","volume":"124","year":"1956","journal-title":"J Nerv Ment Dis"},{"key":"key20211231064346_B36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00005053-197607000-00006","article-title":"A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients","volume":"163","year":"1976","journal-title":"J Nerv Ment Dis"},{"key":"key20211231064346_B37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WNF.0b013e31826249bb","article-title":"The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis","volume":"35","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"key20211231064346_B38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key20211231064346_B39","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1528-1157.2000.tb04610.x","article-title":"The \u2018forgotten\u2019 cross-tolerance between phenobarbital and primidone: It can prevent acute primidone-related toxicity","volume":"41","year":"2000","journal-title":"Epilepsia"},{"key":"key20211231064346_B40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.23.2.145","article-title":"Primidone, diphenylhydantoin and phenobarbital: Aspects of acute and chronic toxicity","volume":"23","year":"1973","journal-title":"Neurology"},{"key":"key20211231064346_B41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/2211556007666180425143506","article-title":"Systemic Injections of Primidone Cause Wake-Inducing Effects in Rats","volume":"8","year":"2019","journal-title":"Curr Psychopharmacol"},{"key":"key20211231064346_B42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5334\/tohm.284","article-title":"Non-motor symptoms of essential tremor are independent of tremor severity and have an impact on quality of life","volume":"6","year":"2016","journal-title":"Tremor and Other Hyperkinetic Movements"},{"issue":"Suppl 1","key":"key20211231064346_B43","first-page":"S115","article-title":"Non-motor symptoms in essential tremor: A review of the current data and state of the field","volume":"22","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"key20211231064346_B44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jns.2016.10.006","article-title":"Daytime sleepiness and nighttime sleep quality across the full spectrum of cognitive presentations in essential tremor","volume":"371","year":"2016","journal-title":"J Neurol Sci"},{"key":"key20211231064346_B45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-0404.2011.01573.x","article-title":"Non-motor features in essential tremor","volume":"125","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"key20211231064346_B46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13760-014-0396-6","article-title":"Cognitive functions, fatigue, depression, anxiety, and sleep disturbances: assessment of nonmotor features in young patients with essential tremor","volume":"115","year":"2015","journal-title":"Acta Neurol Belg"},{"key":"key20211231064346_B47","article-title":"Prospective Longitudinal Study of Gait and Balance in a Cohort of Elderly Essential Tremor Patients","volume":"11","journal-title":"Front Neurol"},{"key":"key20211231064346_B48","article-title":"Ataxic gait in essential tremor: A disease-associated feature?","volume":"9","journal-title":"Tremor and Other Hyperkinetic Movements"},{"key":"key20211231064346_B49","doi-asserted-by":"crossref","first-page":"13592","DOI":"10.1073\/pnas.1817689116","article-title":"Role of cerebellar GABAergic dysfunctions in the origins of essential tremor","volume":"116","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"key20211231064346_B50","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.2174\/0929867325666181112094330","article-title":"An Update on the Neurochemistry of Essential Tremor","volume":"27","year":"2020","journal-title":"Curr Med Chem"},{"key":"key20211231064346_B51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5334\/tohm.229","article-title":"The GABA Hypothesis in Essential Tremor: Lights and Shadows","volume":"4","year":"2014","journal-title":"Tremor and Other Hyperkinetic Movements"},{"key":"key20211231064346_B52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41582-019-0302-1","article-title":"Essential tremor pathology: neurodegeneration and reorganization of neuronal connections","volume":"16","year":"2020","journal-title":"Nat Rev Neurol"}],"container-title":["Tremor and Other Hyperkinetic Movements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/doi.org\/10.5334\/tohm.672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T02:02:51Z","timestamp":1700013771000},"score":1,"resource":{"primary":{"URL":"https:\/\/tremorjournal.org\/articles\/10.5334\/tohm.672\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12,31]]}},"alternative-id":["10.5334\/tohm.672"],"URL":"https:\/\/doi.org\/10.5334\/tohm.672","relation":{},"ISSN":["2160-8288"],"issn-type":[{"value":"2160-8288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"57"}}